Please assess the completion status of the following clinical trial:

Trial Title: Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Study participants must meet all of the following inclusion criteria to participate in the study:~* Adult female study participants (≥18 years) with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel~* Study participants must be capable and willing to provide informed consent, and be willing and able to complete the study questionnaires during the study~Exclusion Criteria:~Study participants who fulfill any of the following criteria will be excluded:~* Patients with metastatic breast cancer~* History of other cancers (except squamous and basal cell carcinoma)~* Autoimmune disorders~* Presence of major active infection for which antibiotics and/or antivirals are prescribed within the last 14 days (chronic or acute, eg, sepsis, HIV, pneumonia, active COVID infection)~* Pregnant women~* Participation in an additional study at the time of enrollment where the intervention could potentially alter CIPN risk (unless in the control arm)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study group (Type: None): Adult females with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).